8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________

FORM 8-K

______________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  January 3, 2012

______________

Stellar Pharmaceuticals Inc.

(Exact name of registrant as specified in its charter)

______________

Ontario, Canada	0-31198	Not Applicable
(State or Other Jurisdiction	(Commission	(I.R.S. Employer
of Incorporation)	File Number)	Identification No.)

544 Egerton Street, London, Ontario, Canada, N5W 3Z8

(Address of Principal Executive Office) (Zip Code)

(519) 434-1540

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

See Exhibit 99.1

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Conference Call Press Release

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

STELLAR PHARMACEUTICALS INC.
By:	/s/ Scott Langille
	Scott Langille Chief Financial Officer

Date:  January 3, 2012

 3

EX-99.1

EXHIBIT 99.1

  Press Release For Immediate Release Source: Stellar Pharmaceuticals Inc. & Tribute Pharmaceuticals

MILTON, ON, January 3, 2011 – Stellar Pharmaceuticals Inc. ("Stellar") (OTCQB:SLXCF; OTCBB:SLXCF; PINK SHEETS: SLXCF), a Canadian public company) announced today that the Company intends host a conference call at 4:00 p.m. Eastern Time on Tuesday, January 3, 2012 to discuss the details of the MycoVa™ agreement entered into with Apricus Biosciences, Inc. on December 30, 2011 as noted in the press release dated today’s date. The dial-in number to access the call is US/Canada 866-226-1792, International 416-340-2216.

A taped replay of the conference call will also be available beginning approximately two hours after the call's conclusion and will remain available through 12:00 midnight Eastern Time on January 10, 2012. The replay may be accessed by dialing 800-408-3053 and entering Pass code 5157460. From international locations, the replay may be accessed by dialing 905-694-9451. To access the webcast, go to Stellar Web site at http://stellarpharma.com. A replay of the webcast will also be available.

About Stellar Pharmaceuticals Inc.

Stellar Pharma and its subsidiary, Tribute Pharmaceuticals, is an emerging Canadian specialty pharmaceutical company focused on the acquisition, licensing, development and management of pharmaceutical and healthcare products with its primary focus on the Canadian market.  Stellar Pharma currently competes in the dermatology market in Canada with its promotion of Soriatane®* (acitretin).

Stellar also markets Bezalip®* SR (bezafibrate) NeoVisc® (1.0% sodium hyaluronate solution) and Uracyst® (sodium chondroitin sulfate solution 2%) in the Canadian market place and is awaiting regulatory approval for Cambia®** (diclofenac potassium for oral solution) in Canada.  Additionally, NeoVisc and Uracyst are commercially available in 58 countries and are sold globally through various international partnerships.  Stellar is currently in negotiations to license both NeoVisc and Uracyst in the US and other international markets.

For further information on Stellar Pharma, visit http://www.stellarpharma.com and for information on its subsidiary please visit http://www.tributepharma.com.

*Soriatane and Bezalip are registered trademarks and under license from Actavis Group PTC ehf

**Cambia is a registered trademark and under license from Nautilus Neurosciences, Inc.

Contacts:

Stellar Pharmaceuticals Inc.

Scott Langille CFO 519-434-1540 scott.langille@stellarpharma.com       or Arnold Tenney Chairman 705-445-9505